Male Hypogonadism - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 75 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Male Hypogonadism - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Male Hypogonadism - Pipeline Review, H2 2014', provides an overview of the Male Hypogonadism's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Male Hypogonadism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Male Hypogonadism and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Male Hypogonadism and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Male Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Male Hypogonadism pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Male Hypogonadism Overview 7
Therapeutics Development 8
Pipeline Products for Male Hypogonadism - Overview 8
Pipeline Products for Male Hypogonadism - Comparative Analysis 9
Male Hypogonadism - Therapeutics under Development by Companies 10
Male Hypogonadism - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Male Hypogonadism - Products under Development by Companies 15
Male Hypogonadism - Companies Involved in Therapeutics Development 16
Antares Pharma, Inc. 16
Auxilium Pharmaceuticals, Inc. 17
Clarus Therapeutics, Inc. 18
Diurnal Ltd 19
EndoCeutics, Inc. 20
Ferring International Center S.A. 21
Forendo Pharma Oy 22
Lipocine Inc. 23
M et P Pharma AG 24
Monosol Rx, LLC 25
Pantarhei Bioscience BV 26
SoluBest Ltd. 27
Male Hypogonadism - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 36
fispemifene - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Libidua - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LPCN-1021 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
LPCN-1111 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
T-2 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Testavan - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
testosterone - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
testosterone - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
testosterone - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
testosterone enanthate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
testosterone propionate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
testosterone undecanoate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
testosterone undecanoate - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
testosterone undecanoate - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
testosterone undecanoate - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
testosterone undecanoate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Male Hypogonadism - Recent Pipeline Updates 57
Male Hypogonadism - Dormant Projects 64
Male Hypogonadism - Discontinued Products 65
Male Hypogonadism - Product Development Milestones 66
Featured News & Press Releases 66
Oct 13, 2014: Lipocine Announces Positive Top-Line Results in Phase 2a Study of LPCN 1111 66
Sep 24, 2014: Lipocine Announces Positive Top-Line Results in Its Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy 66
Sep 23, 2014: Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Phase 3 Study of LPCN 1021 68
Sep 18, 2014: Clarus Therapeutics Reports FDA Advisory Committees Vote on REXTORO for Low Testosterone in Men 68
Jul 22, 2014: Antares Pharma Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males 69
Jul 15, 2014: Lipocine Announces Issuance of U.S. Patent for LPCN 1021 70
Jun 22, 2014: Clarus Therapeutics Presents Phase 3 Data for REXTORO for Men With Hypogonadism 70
May 28, 2014: Clarus Therapeutics to Present Phase 3 Data for REXTORO at ICE/ENDO 2014 72
May 28, 2014: Trimel Receives FDA Approval for Natesto Nasal Gel to Treat Men with Low Testosterone 72
May 27, 2014: Lipocine Announces First Patient Dosed in Phase 2a Study of LPCN 1111, a Novel Testosterone Ester for Oral Testosterone Replacement Therapy 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
Number of Products under Development for Male Hypogonadism, H2 2014 8
Number of Products under Development for Male Hypogonadism - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Male Hypogonadism - Pipeline by Antares Pharma, Inc., H2 2014 16
Male Hypogonadism - Pipeline by Auxilium Pharmaceuticals, Inc., H2 2014 17
Male Hypogonadism - Pipeline by Clarus Therapeutics, Inc., H2 2014 18
Male Hypogonadism - Pipeline by Diurnal Ltd, H2 2014 19
Male Hypogonadism - Pipeline by EndoCeutics, Inc., H2 2014 20
Male Hypogonadism - Pipeline by Ferring International Center S.A., H2 2014 21
Male Hypogonadism - Pipeline by Forendo Pharma Oy, H2 2014 22
Male Hypogonadism - Pipeline by Lipocine Inc., H2 2014 23
Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2014 24
Male Hypogonadism - Pipeline by Monosol Rx, LLC, H2 2014 25
Male Hypogonadism - Pipeline by Pantarhei Bioscience BV, H2 2014 26
Male Hypogonadism - Pipeline by SoluBest Ltd., H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 35
Male Hypogonadism Therapeutics - Recent Pipeline Updates, H2 2014 57
Male Hypogonadism - Dormant Projects, H2 2014 64
Male Hypogonadism - Discontinued Products, H2 2014 65